Mr. Miles joined Agios in 2015 and currently serves as chief commercial officer. He previously served as SVP U.S. commercial and global marketing as well as vice president, oncology program leadership, where he was instrumental in setting the strategy for the IDH portfolio and leading the program team through the development and approval of TIBSOVO®. Prior to joining Agios, he spent 14 years at Genentech, where he held roles of increasing responsibility including marketing, sales management, reimbursement and lifecycle leadership supporting a broad portfolio of brands including Rituxan®, Herceptin®, Tarceva® and Lucentis®. Mr. Miles also led the U.S. launches of next generation anti-HER2 treatments Perjeta® and Kadcyla®. Prior to Genentech, he spent a number of years at ALZA Corporation and SmithKline Beecham (now GSK) in numerous roles including marketing, market analytics and organization development. Mr. Miles holds a B.S. in applied economics with a minor in biological sciences from Cornell University.